J Rheum Dis.  2023 Apr;30(2):88-98. 10.4078/jrd.2022.0001.

Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean

• Ahn JK

• KMID: 2541052
• DOI: http://doi.org/10.4078/jrd.2022.0001

Abstract

Gout is the most common form of inflammatory arthritis that affects mainly middle-aged men, and there is clear evidence of an association between hyperuricemia and the risk for gout. Increasing prevalence of gout and hyperuricemia has been reported in many countries. The prevalence of gout and hyperuricemia are constantly increasing in Korea with the patients at risk for developing a variety of comorbidities. Although there have been studies on the association between gout or serum uric acid level and several neurodegenerative diseases, cancer, and cardiovascular mortality, the causal relationship between gout and these comorbidities are still unclear. The associations of substantial economic burden with hyperuricemia, gout attack, and suboptimal treatment are well known. Gout is a disease that requires lifelong management including lifestyle modification. However, gout is poorly managed worldwide although effective urate-lowering drugs exist. In this review, we addressed epidemiological studies and treatment-related problems in the Korean population with gout or hyperuricemia to obtain the best clinical outcomes and reduce their medical burden.

Keyword

Gout; Hyperuricemia; Epidemiology; Comorbidity; Treatment

Figure

• 

  Fig. 1 Worldwide prevalence ranges of hyperuricemia by country and time. JMDC: Japan Medical Data Center, J-SHC: Japan Specific Health Checkups study, KNHANES: Korean National Health and Nutrition Examination Survey, KoGES: Korean Genome and Epidemiology Study, NAHSIT: Nutrition and Health Survey in Taiwan, NHANES: National Health and Nutrition Examination Survey.

• 

  Fig. 2 Worldwide prevalence ranges of gout by country and time. BNHI: Bureau of National Health Insurance, DNPR: Danish National Patient Register, GPRD: General Practice Research Database, HIRA: Health Insurance Review & Assessment data, JMDC: Japan Medical Data Center, NHANES: National Health and Nutrition Examination Survey, PopData: PopulationData BC (British Columbia).

Reference

1. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. 2019; Gout. Nat Rev Dis Primers. 5:69. DOI: 10.1038/s41572-019-0115-y. PMID: 31558729.

2. Wertheimer A, Morlock R, Becker MA. 2013; A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 75:1–4. DOI: 10.1016/j.curtheres.2013.04.003. PMID: 24465034. PMCID: PMC3898191.

3. Dehlin M, Jacobsson L, Roddy E. 2020; Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 16:380–90. DOI: 10.1038/s41584-020-0441-1. PMID: 32541923.

4. Choi HK, McCormick N, Yokose C. 2022; Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 18:97–111. DOI: 10.1038/s41584-021-00725-9. PMID: 34921301.

5. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. 2008; Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 28:437–43. DOI: 10.1592/phco.28.4.437. PMID: 18363527. PMCID: PMC2737273.

6. Zhu Y, Pandya BJ, Choi HK. 2011; Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63:3136–41. DOI: 10.1002/art.30520. PMID: 21800283.

7. Otaki Y, Konta T, Ichikawa K, Fujimoto S, Iseki K, Moriyama T, et al. 2021; Possible burden of hyperuricaemia on mortality in a community-based population: a large-scale cohort study. Sci Rep. 11:8999. DOI: 10.1038/s41598-021-88631-8. PMID: 33903733. PMCID: PMC8076257.

8. Koto R, Nakajima A, Horiuchi H, Yamanaka H. 2021; Real-world treatment of gout and asymptomatic hyperuricemia: a cross-sectional study of Japanese health insurance claims data. Mod Rheumatol. 31:261–9. DOI: 10.1080/14397595.2020.1784556. PMID: 32552370.

9. Chuang SY, Lee SC, Hsieh YT, Pan WH. 2011; Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 20:301–8.

10. Ryu S, Chang Y, Zhang Y, Kim SG, Cho J, Son HJ, et al. 2012; A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol. 175:133–43. DOI: 10.1093/aje/kwr291. PMID: 22156041.

11. Kim EH, Jeon K, Park KW, Kim HJ, Ahn JK, Jeon CH, et al. 2004; The prevalence of gout among hyperuricemic population. J Korean Rheum Assoc. 11:7–13.

12. Hong SJ, Kim YS, Kim HS. 2012; Prevalence and clinical features of hyperuricemia in Gwangju and Jeonnam territories. J Rheum Dis. 19:138–46. DOI: 10.4078/jrd.2012.19.3.138.

13. Kim Y, Kang J, Kim GT. 2018; Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 37:2529–38. DOI: 10.1007/s10067-018-4130-2. PMID: 29790110.

14. Koo BS, Jeong HJ, Son CN, Kim SH, Kim HJ, Kim GH, et al. 2021; Distribution of serum uric acid levels and prevalence of hyper- and hypouricemia in a Korean general population of 172,970. Korean J Intern Med. 36(Suppl 1):S264–72. DOI: 10.3904/kjim.2020.116. PMID: 33227843. PMCID: PMC8009145.

15. Rai SK, Aviña-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC, et al. 2017; The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum. 46:451–6. DOI: 10.1016/j.semarthrit.2016.08.006. PMID: 28040245. PMCID: PMC5315679.

16. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. 2019; Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 71:991–9. DOI: 10.1002/art.40807. PMID: 30618180. PMCID: PMC6536335.

17. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. 2010; The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 11:98. DOI: 10.1186/1471-2474-11-98. PMID: 20504294. PMCID: PMC2890601.

18. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. 2015; Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 74:661–7. DOI: 10.1136/annrheumdis-2013-204463. PMID: 24431399. PMCID: PMC4392307.

19. Zobbe K, Prieto-Alhambra D, Cordtz R, Højgaard P, Hindrup JS, Kristensen LE, et al. 2019; Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford). 58:836–9. DOI: 10.1093/rheumatology/key390. PMID: 30590724.

20. Klemp P, Stansfield SA, Castle B, Robertson MC. 1997; Gout is on the increase in New Zealand. Ann Rheum Dis. 56:22–6. DOI: 10.1136/ard.56.1.22. PMID: 9059136. PMCID: PMC1752259.

21. Tu FY, Lin GT, Lee SS, Tung YC, Tu HP, Chiang HC. 2015; Prevalence of gout with comorbidity aggregations in southern Taiwan. Joint Bone Spine. 82:45–51. DOI: 10.1016/j.jbspin.2014.07.002. PMID: 25238950.

22. Huang J, Ma ZF, Zhang Y, Wan Z, Li Y, Zhou H, et al. 2020; Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. Glob Health Res Policy. 5:52. DOI: 10.1186/s41256-020-00178-9. PMID: 33292806. PMCID: PMC7708223.

23. Kuo CF, Grainge MJ, Zhang W, Doherty M. 2015; Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 11:649–62. DOI: 10.1038/nrrheum.2015.91. PMID: 26150127.

24. Hakoda M, Kasagi F. 2019; Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol. 29:880–4. DOI: 10.1080/14397595.2018.1519149. PMID: 30175646.

25. Lee CH, Sung NY. 2011; The prevalence and features of Korean gout patients using the National Health Insurance Corporation database. J Rheum Dis. 18:94–100. DOI: 10.4078/jrd.2011.18.2.94.

26. Kim JW, Kwak SG, Lee H, Kim SK, Choe JY, Park SH. 2017; Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015. Rheumatol Int. 37:1499–506. DOI: 10.1007/s00296-017-3768-4. PMID: 28676911.

27. Park JS, Kang M, Song JS, Lim HS, Lee CH. 2020; Trends of gout prevalence in South Korea based on medical utilization: a National Health Insurance Service database (2002~2015). J Rheum Dis. 27:174–81. DOI: 10.4078/jrd.2020.27.3.174.

28. Choi HK, Ford ES, Li C, Curhan G. 2007; Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 57:109–15. DOI: 10.1002/art.22466. PMID: 17266099.

29. Moon KW, Kim MJ, Choi IA, Shin K. 2022; Cardiovascular risks in Korean patients with gout: analysis using a National Health Insurance Service database. J Clin Med. 11:2124. DOI: 10.3390/jcm11082124. PMID: 35456221. PMCID: PMC9030984.

30. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. 2004; Prevalence of the metabolic syndrome in patients with gout. J Korean Rheum Assoc. 11:349–57.

31. Jung JH, Song GG, Ji JD, Lee YH, Kim JH, Seo YH, et al. 2018; Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med. 33:815–22. DOI: 10.3904/kjim.2016.062. PMID: 27729624. PMCID: PMC6030414.

32. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. 2005; The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 20:1029–33. DOI: 10.3346/jkms.2005.20.6.1029. PMID: 16361817. PMCID: PMC2779304.

33. Cho SK, Chang Y, Kim I, Ryu S. 2018; U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol. 70:1122–32. DOI: 10.1002/art.40472. PMID: 29694719.

34. Abraham A, Drory VE. 2014; Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 261:1133–8. DOI: 10.1007/s00415-014-7331-x. PMID: 24699859.

35. Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, et al. 2017; Serum uric acid levels in patients with Parkinson's disease: a meta-analysis. PLoS One. 12:e0173731. DOI: 10.1371/journal.pone.0173731. PMID: 28319195. PMCID: PMC5358777.

36. Khan AA, Quinn TJ, Hewitt J, Fan Y, Dawson J. 2016; Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Age (Dordr). 38:16. DOI: 10.1007/s11357-016-9871-8. PMID: 26820749. PMCID: PMC5005871.

37. Latourte A, Soumaré A, Bardin T, Perez-Ruiz F, Debette S, Richette P. 2018; Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 77:328–35. DOI: 10.1136/annrheumdis-2016-210767. PMID: 28754803.

38. Singh JA, Cleveland JD. 2019; Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data. BMC Neurol. 19:4. DOI: 10.1186/s12883-018-1234-x. PMID: 30611222. PMCID: PMC6321725.

39. Kim JH, Choi IA, Kim A, Kang G. 2021; Clinical association between gout and Parkinson's disease: a nationwide population-based cohort study in Korea. Medicina (Kaunas). 57:1292. DOI: 10.3390/medicina57121292. PMID: 34946237. PMCID: PMC8704991.

40. Kim JH, Yim DH, Choi IA, Lee J, Park H, Eom SY. DOI: 10.1002/acr.24959. PMID: 35604886.

41. Hu LY, Yang AC, Lee SC, You ZH, Tsai SJ, Hu CK, et al. 2020; Risk of Parkinson's disease following gout: a population-based retrospective cohort study in Taiwan. BMC Neurol. 20:338. DOI: 10.1186/s12883-020-01916-9. PMID: 32900384. PMCID: PMC7487828.

42. Fini MA, Elias A, Johnson RJ, Wright RM. 2012; Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 1:16. DOI: 10.1186/2001-1326-1-16. PMID: 23369448. PMCID: PMC3560981.

43. Slobodnick A, Krasnokutsky S, Lehmann RA, Keenan RT, Quach J, Francois F, et al. 2019; Colorectal cancer among gout patients undergoing colonoscopy. J Clin Rheumatol. 25:335–40. DOI: 10.1097/RHU.0000000000000893. PMID: 31764494.

44. Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH. 2012; Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine. 79:375–8. DOI: 10.1016/j.jbspin.2011.09.011. PMID: 22088929.

45. Boffetta P, Nordenvall C, Nyrén O, Ye W. 2009; A prospective study of gout and cancer. Eur J Cancer Prev. 18:127–32. DOI: 10.1097/CEJ.0b013e328313631a. PMID: 19337060.

46. Xie Y, Xu P, Liu K, Lin S, Wang M, Tian T, et al. 2019; Hyperuricemia and gout are associated with cancer incidence and mortality: a meta-analysis based on cohort studies. J Cell Physiol. 234:14364–76. DOI: 10.1002/jcp.28138. PMID: 30693505.

47. Oh YJ, Lee YJ, Lee E, Park B, Kwon JW, Heo J, et al. 2022; Cancer risk in Korean patients with gout. Korean J Intern Med. 37:460–7. DOI: 10.3904/kjim.2020.259. PMID: 32872748. PMCID: PMC8925955.

48. Lee JS, Myung J, Lee HA, Hong S, Lee CK, Yoo B, et al. 2021; Risk of cancer in middle-aged patients with gout: a nationwide population-based study in Korea. J Rheumatol. 48:1465–71. DOI: 10.3899/jrheum.200497. PMID: 33191287.

49. Song JU, Hwang J, Ahn JK. 2017; Serum uric acid is positively associated with pulmonary function in Korean health screening examinees. Mod Rheumatol. 27:1057–65. DOI: 10.1080/14397595.2017.1285981. PMID: 28693364.

50. Ahn JK, Hwang J, Hwang JH, Yoon WT, Chung PW, Ryu S. 2018; The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans. Nutr Metab Cardiovasc Dis. 28:14–22. DOI: 10.1016/j.numecd.2017.10.019. PMID: 29191476.

51. Hwang J, Hwang JH, Chung SM, Kwon MJ, Ahn JK. 2018; Association between serum uric acid and arterial stiffness in a low-risk, middle-aged, large Korean population: a cross-sectional study. Medicine (Baltimore). 97:e12086. DOI: 10.1097/MD.0000000000012086. PMID: 30200090. PMCID: PMC6133619.

52. Hwang J, Hwang JH, Ryu S, Ahn JK. 2019; Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study. J Bone Miner Metab. 37:142–51. DOI: 10.1007/s00774-018-0905-4. PMID: 29372335.

53. Hwang J, Ryu S, Ahn JK. 2022; Higher levels of serum uric acid have a significant association with lower incidence of lower urinary tract symptoms in healthy Korean men. Metabolites. 12:649. DOI: 10.3390/metabo12070649. PMID: 35888773. PMCID: PMC9322789.

54. Lee KW, Shin D. 2022; Concurrent presence of high serum uric acid and inflammation is associated with increased incidence of type 2 diabetes mellitus in Korean adult population. Sci Rep. 12:11000. DOI: 10.1038/s41598-022-15176-9. PMID: 35768559. PMCID: PMC9243007.

55. Jeong H, Baek SY, Kim SW, Park EJ, Kim H, Lee J, et al. 2021; Gender-specific association of serum uric acid and pulmonary function: data from the Korea National Health and Nutrition Examination Survey. Medicina (Kaunas). 57:953. DOI: 10.3390/medicina57090953. PMID: 34577876. PMCID: PMC8465554.

56. Lee YH, Song GG. 2019; Uric acid level, gout and bone mineral density: a Mendelian randomization study. Eur J Clin Invest. 49:e13156. DOI: 10.1111/eci.13156.

57. Kim K, Kang K, Sheol H, Shin J, Sim Y, Yang T, et al. 2022; The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients. Int J Environ Res Public Health. 19:1042. DOI: 10.3390/ijerph19031042. PMID: 35162067. PMCID: PMC8834479.

58. Janssens HJ, Arts PG, Schalk BW, Biermans MC. 2017; Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: a primary care retrospective cohort study. Joint Bone Spine. 84:59–64. DOI: 10.1016/j.jbspin.2015.12.003. PMID: 27236260.

59. Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. 2015; The economic burden of gout: a systematic review. Semin Arthritis Rheum. 45:75–80. DOI: 10.1016/j.semarthrit.2015.02.004. PMID: 25912932.

60. Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. 2003; A literature review of the epidemiology and treatment of acute gout. Clin Ther. 25:1593–617. DOI: 10.1016/S0149-2918(03)80158-3. PMID: 12860487.

61. Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. 2019; The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 22:1–6. DOI: 10.1080/13696998.2018.1532904. PMID: 30289009.

62. Son KM, Kim JR, Park HA, Kim HA. 2022; Trends in hospital visits and healthcare costs of gout and seropositive rheumatoid arthritis in Korea from 2010 to 2017 using National Healthcare Claims. Korean J Intern Med. 37:681–90. DOI: 10.3904/kjim.2020.322. PMID: 34695882. PMCID: PMC9082448.

63. Nielsen SM, Bartels EM, Henriksen M, Wæhrens EE, Gudbergsen H, Bliddal H, et al. 2017; Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 76:1870–82. DOI: 10.1136/annrheumdis-2017-211472. PMID: 28866649. PMCID: PMC5705854.

64. Zhu Y, Zhang Y, Choi HK. 2010; The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford). 49:2391–9. DOI: 10.1093/rheumatology/keq256. PMID: 20805117. PMCID: PMC2981511.

65. Dalbeth N, Chen P, White M, Gamble GD, Barratt-Boyes C, Gow PJ, et al. 2014; Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 73:797–802. DOI: 10.1136/annrheumdis-2013-203970. PMID: 24255548.

66. Ahn JK, Hwang J, Lee MY, Kang M, Hwang J, Koh EM, et al. 2021; How much does fat mass change affect serum uric acid levels among apparently clinically healthy Korean men? Ther Adv Musculoskelet Dis. 13:1759720X21993253. DOI: 10.1177/1759720X21993253. PMID: 33708266. PMCID: PMC7907717.

67. Hwang J, Lee MY, Ahn JK, Cha HS. 2022; Relationship between changing body mass index and serum uric acid alteration among clinically apparently healthy Korean men. Arthritis Care Res (Hoboken). 74:1277–86. DOI: 10.1002/acr.24576. PMID: 33544980.

68. Perez-Ruiz F, Desideri G. 2018; Improving adherence to gout therapy: an expert review. Ther Clin Risk Manag. 14:793–802. DOI: 10.2147/TCRM.S162956. PMID: 29765222. PMCID: PMC5939914.

69. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. 2009; Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 25:1711–9. DOI: 10.1185/03007990903017966. PMID: 19485724.

70. Scheepers LEJM, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. 2018; Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 47:689–702. DOI: 10.1016/j.semarthrit.2017.09.007. PMID: 29198878.

71. Lee S, So MW. 2016; Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting. Mod Rheumatol. 26:950–5. DOI: 10.3109/14397595.2016.1170914. PMID: 27142782.

72. Lee S, So MW, Ahn E. 2019; Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting. Mod Rheumatol. 29:662–8. DOI: 10.1080/14397595.2018.1483293. PMID: 29856667.

73. Chung MK, Kim SS, Cheon YH, Hong SJ, Choi HJ, Seo MR, et al. 2021; Patient perspectives and preferences regarding gout and gout management: impact on adherence. J Korean Med Sci. 36:e208. DOI: 10.3346/jkms.2021.36.e208. PMID: 34402226. PMCID: PMC8369315.

74. Kim JW, Kwak SG, Park SH. 2018; Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database. Korean J Intern Med. 33:228–9. DOI: 10.3904/kjim.2016.429. PMID: 28823114. PMCID: PMC5768547.

75. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. 2008; Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59:1540–8. DOI: 10.1002/art.24209. PMID: 18975369.

76. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. 2005; Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 353:2450–61. DOI: 10.1056/NEJMoa050373. PMID: 16339094.

77. Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. 2020; Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 396:1745–57. DOI: 10.1016/S0140-6736(20)32234-0. PMID: 33181081.

78. Pawar A, Desai RJ, Liu J, Kim E, Kim SC. 2021; Updated assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. J Am Heart Assoc. 10:e020045. DOI: 10.1161/JAHA.120.020045. PMID: 33764153. PMCID: PMC8174329.

79. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. 2018; Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation. 138:1116–26. DOI: 10.1161/CIRCULATIONAHA.118.033992. PMID: 29899013. PMCID: PMC6202230.

80. Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW, et al. 2019; Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 58:2122–9. DOI: 10.1093/rheumatology/kez189. PMID: 31098635.

81. Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. 2020; Rapid reduction in uric acid by a urate-lowering agent is associated with recurrent cardiovascular events. Med Hypotheses. 141:109740. DOI: 10.1016/j.mehy.2020.109740. PMID: 32305810.

82. Ghang BZ, Lee JS, Choi J, Kim J, Yoo B. 2022; Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 8:e001944. DOI: 10.1136/rmdopen-2021-001944. PMID: 35732345. PMCID: PMC9226988.

83. Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. 2014; Non-adherence to cardiovascular medications. Eur Heart J. 35:3267–76. DOI: 10.1093/eurheartj/ehu364. PMID: 25265973.

84. Kang EH, Park EH, Shin A, Song JS, Kim SC. 2021; Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J. 42:4578–88. DOI: 10.1093/eurheartj/ehab619. PMID: 34508567. PMCID: PMC8633759.

85. Eun Y, Han H, Kim K, Kang S, Lee S, Kim H, et al. 2022; Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout. Ther Adv Musculoskelet Dis. 14:1759720X221116409. DOI: 10.1177/1759720X221116409. PMID: 35966182. PMCID: PMC9373176.

86. Lee KW, Oh DH, Lee C, Yang SY. 2005; Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 65:437–47. DOI: 10.1111/j.1399-0039.2005.00386.x. PMID: 15853898.

87. González-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. 2015; Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43(Database issue):D784–8. DOI: 10.1093/nar/gku1166. PMID: 25414323. PMCID: PMC4383964.

88. Park DJ, Kang JH, Lee JW, Lee KE, Wen L, Kim TJ, et al. 2015; Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken). 67:280–7. DOI: 10.1002/acr.22409. PMID: 25047754.

89. Park HW, Kim DK, Kim SH, Kim S, Chae DW, Yang MS, et al. 2019; Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-a prospective study. J Allergy Clin Immunol Pract. 7:1271–6. DOI: 10.1016/j.jaip.2018.12.012. PMID: 30580048.

90. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020; 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 72:879–95. Erratum. DOI: 10.1002/art.41688. PMID: 33638303.

91. Ahn E, Lee S, Lee HN, Lee SG, So MW. 2019; Comparison of efficacy and safety of febuxostat in gout patients with chronic kidney disease stage 3 and stage 4/5. J Rheum Dis. 26:118–23. DOI: 10.4078/jrd.2019.26.2.118.

92. Choi SY, Choi SW, Lee S, So MW, Oh JS, Lim DH. 2021; Efficacy and tolerability of febuxostat in gout patients on dialysis. Intern Med J. 51:348–54. DOI: 10.1111/imj.14776. PMID: 32043690.